Warren R, Conrad C, Foley P, Iversen L, Langley R, Kokolakis G, Davis L, Vanvoorden V, Wiegratz S, Merola J. Bimekizumab versus secukinumab continuous maintenance of response at every visit through one year in patients with moderate to severe plaque psoriasis: Post-hoc results from the BE RADIANT phase 3b trial. J of Skin [Internet]. 2022 Nov. 16 [cited 2024 Jul. 3];6(6):s70. Available from: https://jofskin.org/33014/index.php/skin/article/view/1826